Immatics publishes Phase 1 presentation on IMA203CD8 cell therapy in solid tumors
IMTX•Immatics published an ESMO presentation reporting Phase 1 results for its investigational PRAME-directed T-cell therapy IMA203CD8. The objective response rate was 51% among 90 evaluable patients, and the confirmed response rate was 41%.
1. Phase 1 results
Among 20 patients with gynecologic cancers treated at a higher dose, the objective response rate was 60%, with confirmed responses in 55%. Responses remained ongoing beyond 2.5 years across indications; dose-limiting toxicities occurred in four of 98 patients, and the maximum tolerated dose was not reached at 12.5 billion cells.
